Michael S. Blaiss
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael S. Blaiss has a total of 266 co-authors. Here are the top co-authors by number of shared publications:
- Juby Anne Jacob-Nara
Sanofi
5 shared publications - Asif Hameed Khan
Global Medical, Sanofi, Bridgewater, NJ, USA
3 shared publications David P. Skoner
Allergheny Health Network, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA
3 shared publications- Harold S. Nelson
National Jewish Health, Denver, Colo
3 shared publications A. Pawar
Sanofi, Cambridge, MA, United States
2 shared publications- Amarjot Kaur
Merck & Co., Inc., Whitehouse Station, NJ USA
2 shared publications
Latest Publications
- 29 October 2025
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 15 (12) , 1436-1438
The Influence of Nasal Cavity Dimensions on Frequency of Treatment for Rhinitis Symptoms
Key Points: A wearable headband treats nasal congestion using acoustic resonance and AI‐estimated anatomy. Individuals with higher nasal depth‐to‐height ratio used acoustic therapy more often. Depth‐to‐height ratio may be an anatomical marker for increased nasal congestion risk
- 29 October 2025
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 15 (12) , 1436-1438
The Influence of Nasal Cavity Dimensions on Frequency of Treatment for Rhinitis Symptoms
Key Points: A wearable headband treats nasal congestion using acoustic resonance and AI‐estimated anatomy. Individuals with higher nasal depth‐to‐height ratio used acoustic therapy more often. Depth‐to‐height ratio may be an anatomical marker for increased nasal congestion risk
- 1 September 2025
- Published by Oceanside Publications Inc. in Allergy and Asthma Proceedings
- Vol. 46 (5) , 388-397
Impact of nasal congestion on intranasal rescue medication absorption and efficacy: A systematic review
Background: It is critical for rescue medications to have rapid absorption and onset of action. Although intranasal formulations of rescue medications have advantages over other forms of administration, the impact of nasal congestion on drug absorption has been questioned. Objective: We aimed to determine if nasal congestion impacts the absorption and efficacy of intranasal rescue medications. Methods: A rescue medication is used as needed for the immediate treatment of an episodic medical event that requires urgent intervention. Systematic searches for 15 pre-identified intranasal rescue medications were conducted in PubMED/MEDLINE up to July 2, 2024. Eligible studies were controlled human studies that compared the absorption or efficacy of an identical dose of intranasal rescue medication administered with and without the presence of nasal congestion that was induced by allergen challenge or that was associated with a medical condition (e.g., allergic rhinitis). Results: The searches identified 160 articles; six studies, all open-label, were eligible for final inclusion. Two intranasal epinephrine studies showed increased maximum plasma concentrations after allergen-induced congestion; one of these epinephrine studies also showed a faster time to maximum plasma concentration. Three additional studies that evaluated epinephrine, glucagon, and fentanyl found no effect of congestion on absorption. In the sixth study, congestion had no effect on zolmitriptan efficacy. Conclusion: Available evidence indicates no negative impact of nasal congestion on the absorption of intranasal rescue medications. Congestion may actually increase absorption of some intranasal epinephrine formulations. The impact of congestion on intranasal medication absorption is likely dependent on each drug’s properties, mode of action, and formulation.
- 1 September 2025
- Published by Oceanside Publications Inc. in Allergy and Asthma Proceedings
- Vol. 46 (5) , 388-397
Impact of nasal congestion on intranasal rescue medication absorption and efficacy: A systematic review
Background: It is critical for rescue medications to have rapid absorption and onset of action. Although intranasal formulations of rescue medications have advantages over other forms of administration, the impact of nasal congestion on drug absorption has been questioned. Objective: We aimed to determine if nasal congestion impacts the absorption and efficacy of intranasal rescue medications. Methods: A rescue medication is used as needed for the immediate treatment of an episodic medical event that requires urgent intervention. Systematic searches for 15 pre-identified intranasal rescue medications were conducted in PubMED/MEDLINE up to July 2, 2024. Eligible studies were controlled human studies that compared the absorption or efficacy of an identical dose of intranasal rescue medication administered with and without the presence of nasal congestion that was induced by allergen challenge or that was associated with a medical condition (e.g., allergic rhinitis). Results: The searches identified 160 articles; six studies, all open-label, were eligible for final inclusion. Two intranasal epinephrine studies showed increased maximum plasma concentrations after allergen-induced congestion; one of these epinephrine studies also showed a faster time to maximum plasma concentration. Three additional studies that evaluated epinephrine, glucagon, and fentanyl found no effect of congestion on absorption. In the sixth study, congestion had no effect on zolmitriptan efficacy. Conclusion: Available evidence indicates no negative impact of nasal congestion on the absorption of intranasal rescue medications. Congestion may actually increase absorption of some intranasal epinephrine formulations. The impact of congestion on intranasal medication absorption is likely dependent on each drug’s properties, mode of action, and formulation.
- Open Access
The Minimal Clinically Important Difference in Allergen Immunotherapy: An Evidence‐Based Approach
Background: Regulatory authorities recommend a combination of symptom and medication scores during the grass pollen season as a primary endpoint for Phase III allergen immunotherapy (AIT) trials targeting allergic rhinoconjunctivitis. However, many composite primary endpoint scales exist; none are validated, nor do they have a well‐justified minimal clinically important difference (MCID). Methods: Direct patient feedback from 1071 grass‐allergic patients was obtained to determine the minimally relevant improvement in allergic symptoms and translated into an MCID for the EAACI recommended CSMS 0–6 . Additionally, a clinically relevant threshold for the validated Rhinitis Quality of Life Questionnaire (RQLQ(S)) was determined from studies of registered SLIT products and subsequently used as an anchor to derive the MCID for CSMS 0–6 using the data of a Phase III clinical trial with PQ Grass 27,600 SU (RESONATE). Results: 69% of grass‐allergic patients were satisfied with a 1‐point‐improvement (e.g., from “severe” to “moderate”) in their most severe symptom. This translated into an MCID range for CSMS 0–6 of −0.23 to −0.21 points or −17% to −16%. Furthermore, a −0.34 point difference in RQLQ(S) compared to placebo was justified as clinically meaningful based on Phase III data from 2 registered SLIT grass tablets. Using this RQLQ(S) threshold as an anchor, an MCID of CSMS 0–6 of −0.21 points (−16%) was derived using RESONATE. Conclusions: Both patient feedback and RESONATE results support an average MCID of −0.22 points on the CSMS 0–6 scale and −16% on a composite primary endpoint scale, providing minimal thresholds to be achieved after AIT compared to placebo to conclude a positive Phase III trial outcome.
Open AccessThe Minimal Clinically Important Difference in Allergen Immunotherapy: An Evidence‐Based Approach
Background: Regulatory authorities recommend a combination of symptom and medication scores during the grass pollen season as a primary endpoint for Phase III allergen immunotherapy (AIT) trials targeting allergic rhinoconjunctivitis. However, many composite primary endpoint scales exist; none are validated, nor do they have a well‐justified minimal clinically important difference (MCID). Methods: Direct patient feedback from 1071 grass‐allergic patients was obtained to determine the minimally relevant improvement in allergic symptoms and translated into an MCID for the EAACI recommended CSMS 0–6 . Additionally, a clinically relevant threshold for the validated Rhinitis Quality of Life Questionnaire (RQLQ(S)) was determined from studies of registered SLIT products and subsequently used as an anchor to derive the MCID for CSMS 0–6 using the data of a Phase III clinical trial with PQ Grass 27,600 SU (RESONATE). Results: 69% of grass‐allergic patients were satisfied with a 1‐point‐improvement (e.g., from “severe” to “moderate”) in their most severe symptom. This translated into an MCID range for CSMS 0–6 of −0.23 to −0.21 points or −17% to −16%. Furthermore, a −0.34 point difference in RQLQ(S) compared to placebo was justified as clinically meaningful based on Phase III data from 2 registered SLIT grass tablets. Using this RQLQ(S) threshold as an anchor, an MCID of CSMS 0–6 of −0.21 points (−16%) was derived using RESONATE. Conclusions: Both patient feedback and RESONATE results support an average MCID of −0.22 points on the CSMS 0–6 scale and −16% on a composite primary endpoint scale, providing minimal thresholds to be achieved after AIT compared to placebo to conclude a positive Phase III trial outcome.
- Open Access
- 2 August 2024
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 12, 1447619
Degree of fear of needles and preferred allergy immunotherapy treatment among children with allergic rhinitis: caregiver survey results
Introduction: A child's fear of needles may impact the preferred route of allergy immunotherapy (AIT) when choosing between subcutaneous immunotherapy (allergy shots) or sublingual immunotherapy (SLIT). A survey was conducted to understand caregiver health-seeking behavior for children with allergic rhinitis with or without conjunctivitis (AR/C) and explore if fear of needles impacted AIT decisions.Methods: Caregivers of children ages 5–17 years with AR/C were recruited from the Dynata US research panel to participate in an online survey from May-June 2023. The survey received institutional review board exemption status. SLIT-tablets were described as “under-the-tongue tablets”.Results: About a third (34%) of surveyed caregivers (n = 437) reported their child had a severe fear of needles and 47% reported moderate fear. Of surveyed caregivers, 53% and 43% reported they had discussed allergy shots and SLIT-tablets, respectively, with their child's physician. SLIT-tablets were preferred by 84% of caregivers; 6% preferred injections and 10% had no preference. Caregivers of children with a severe fear of needles had the highest preference for SLIT-tablets (95%) vs. injections (2%); 85% and 60% of caregivers of children with moderate and low fear, respectively, preferred SLIT-tablets. Among caregivers of children with a severe fear of needles, a higher percentage agreed that their child would welcome taking SLIT-tablets than that their child would accept taking an ongoing series of allergy shots (93% vs. 43%, respectively).Conclusions: Most caregivers preferred SLIT-tablets over allergy shots for their child with AR/C. Preference for SLIT-tablets corresponded with the child's degree of fear of needles. Fear of needles should be included in AIT shared decision-making conversations.
- 2 August 2024
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 12, 1447619
Open AccessDegree of fear of needles and preferred allergy immunotherapy treatment among children with allergic rhinitis: caregiver survey results
Introduction: A child's fear of needles may impact the preferred route of allergy immunotherapy (AIT) when choosing between subcutaneous immunotherapy (allergy shots) or sublingual immunotherapy (SLIT). A survey was conducted to understand caregiver health-seeking behavior for children with allergic rhinitis with or without conjunctivitis (AR/C) and explore if fear of needles impacted AIT decisions.Methods: Caregivers of children ages 5–17 years with AR/C were recruited from the Dynata US research panel to participate in an online survey from May-June 2023. The survey received institutional review board exemption status. SLIT-tablets were described as “under-the-tongue tablets”.Results: About a third (34%) of surveyed caregivers (n = 437) reported their child had a severe fear of needles and 47% reported moderate fear. Of surveyed caregivers, 53% and 43% reported they had discussed allergy shots and SLIT-tablets, respectively, with their child's physician. SLIT-tablets were preferred by 84% of caregivers; 6% preferred injections and 10% had no preference. Caregivers of children with a severe fear of needles had the highest preference for SLIT-tablets (95%) vs. injections (2%); 85% and 60% of caregivers of children with moderate and low fear, respectively, preferred SLIT-tablets. Among caregivers of children with a severe fear of needles, a higher percentage agreed that their child would welcome taking SLIT-tablets than that their child would accept taking an ongoing series of allergy shots (93% vs. 43%, respectively).Conclusions: Most caregivers preferred SLIT-tablets over allergy shots for their child with AR/C. Preference for SLIT-tablets corresponded with the child's degree of fear of needles. Fear of needles should be included in AIT shared decision-making conversations.
- Open Access
- 7 March 2024
- Published by BMJ in Archives of Disease in Childhood - Education & Practice Edition
- Vol. 109 (5) , 247-251
How to diagnose IgE-mediated food allergy
Immunoglobulin E (IgE)-mediated food allergy is an immune response, typically to a food protein. Accurate diagnosis reduces unnecessary dietary restrictions and economic and psychological burden on patients and caregivers but relies on a rigorous clinical history, specific IgE diagnostic tests and, where needed, oral food challenge. Increased awareness is needed around which patients to test for IgE-mediated food allergy, as well as terms commonly associated with IgE-mediated food allergy testing, in order to optimise patient diagnosis and management. Herein, we describe approaches to diagnosis of IgE-mediated food allergy, appropriate interpretation of results and risks of overtesting.
- 7 March 2024
- Published by BMJ in Archives of Disease in Childhood - Education & Practice Edition
- Vol. 109 (5) , 247-251
Open AccessHow to diagnose IgE-mediated food allergy
Immunoglobulin E (IgE)-mediated food allergy is an immune response, typically to a food protein. Accurate diagnosis reduces unnecessary dietary restrictions and economic and psychological burden on patients and caregivers but relies on a rigorous clinical history, specific IgE diagnostic tests and, where needed, oral food challenge. Increased awareness is needed around which patients to test for IgE-mediated food allergy, as well as terms commonly associated with IgE-mediated food allergy testing, in order to optimise patient diagnosis and management. Herein, we describe approaches to diagnosis of IgE-mediated food allergy, appropriate interpretation of results and risks of overtesting.
- Open Access
- 2 February 2024
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (6) , 1520-1529.e5
Sublingual Tablet Immunotherapy Improves Quality of Life in Adults With Allergic Rhinoconjunctivitis
- 2 February 2024
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (6) , 1520-1529.e5
Open AccessSublingual Tablet Immunotherapy Improves Quality of Life in Adults With Allergic Rhinoconjunctivitis
- 14 November 2023
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 132 (4) , 463-468.e1
Real-world effectiveness of dupilumab in patients with asthma
- 14 November 2023
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 132 (4) , 463-468.e1
Real-world effectiveness of dupilumab in patients with asthma
- Open Access
- 26 September 2023
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 39 (10) , 1375-1381
Interdisciplinary collaboration in the diagnosis and management of chronic cough: the role and importance of primary care providers
Chronic cough (CC) is associated with many conditions, so identifying contributing causes poses a diagnostic challenge. However, guidelines written for US physicians do not explicitly outline suggested roles for primary care providers (PCPs) in the approach to patients with CC, including refractory or unexplained CC. The objective of this review is to describe the role of PCPs in the diagnosis and treatment of CC in adults. This narrative review draws upon literature (identified via a PubMed search performed January 9, 2023, using primary care/disease state-related terms) and expertise from specialist physicians to provide recommendations for CC management in primary care. Cough is one of the top reasons patients seek care from PCPs; accordingly, PCPs are often the first physicians to conduct workup and initiate treatment. Patients with CC often experience a burdensome cough that lasts for years, have high healthcare resource utilization (HCRU), undergo multiple or failed treatment trials, and have limited success finding an etiology. Although specialist referral may be needed for many diagnostic tests, initial aspects of CC workup and management should be completed in primary care. Often more accessible than specialists, real-world evidence on HCRU suggests PCPs are important stakeholders in diagnosing and managing CC, including during initial workup and treatment for the most common causes of CC (i.e. upper-airway cough syndrome, asthma, noneosinophilic asthmatic bronchitis, and gastroesophageal reflux disease). Thorough workup at the primary care level may facilitate earlier identification of CC cause(s), improving patient journey to diagnosis and management.
- 26 September 2023
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 39 (10) , 1375-1381
Open AccessInterdisciplinary collaboration in the diagnosis and management of chronic cough: the role and importance of primary care providers
Chronic cough (CC) is associated with many conditions, so identifying contributing causes poses a diagnostic challenge. However, guidelines written for US physicians do not explicitly outline suggested roles for primary care providers (PCPs) in the approach to patients with CC, including refractory or unexplained CC. The objective of this review is to describe the role of PCPs in the diagnosis and treatment of CC in adults. This narrative review draws upon literature (identified via a PubMed search performed January 9, 2023, using primary care/disease state-related terms) and expertise from specialist physicians to provide recommendations for CC management in primary care. Cough is one of the top reasons patients seek care from PCPs; accordingly, PCPs are often the first physicians to conduct workup and initiate treatment. Patients with CC often experience a burdensome cough that lasts for years, have high healthcare resource utilization (HCRU), undergo multiple or failed treatment trials, and have limited success finding an etiology. Although specialist referral may be needed for many diagnostic tests, initial aspects of CC workup and management should be completed in primary care. Often more accessible than specialists, real-world evidence on HCRU suggests PCPs are important stakeholders in diagnosing and managing CC, including during initial workup and treatment for the most common causes of CC (i.e. upper-airway cough syndrome, asthma, noneosinophilic asthmatic bronchitis, and gastroesophageal reflux disease). Thorough workup at the primary care level may facilitate earlier identification of CC cause(s), improving patient journey to diagnosis and management.
- Open Access
- 4 June 2023
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 131 (2) , 185-193.e10
Innovations in the treatment of anaphylaxis: A review of recent data
- 4 June 2023
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 131 (2) , 185-193.e10
Open AccessInnovations in the treatment of anaphylaxis: A review of recent data